NO20003775L - FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner - Google Patents

FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner

Info

Publication number
NO20003775L
NO20003775L NO20003775A NO20003775A NO20003775L NO 20003775 L NO20003775 L NO 20003775L NO 20003775 A NO20003775 A NO 20003775A NO 20003775 A NO20003775 A NO 20003775A NO 20003775 L NO20003775 L NO 20003775L
Authority
NO
Norway
Prior art keywords
heat shock
inflammatory diseases
treating inflammatory
shock proteins
response
Prior art date
Application number
NO20003775A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003775D0 (no
Inventor
Erwin W Gelfand
Angela Francisca Haczku
Katalin Veronika Lukacs
Original Assignee
Nat Jewish Med & Res Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Jewish Med & Res Center filed Critical Nat Jewish Med & Res Center
Publication of NO20003775D0 publication Critical patent/NO20003775D0/no
Publication of NO20003775L publication Critical patent/NO20003775L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20003775A 1998-01-23 2000-07-21 FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner NO20003775L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1233098A 1998-01-23 1998-01-23
PCT/US1999/001421 WO1999037319A1 (en) 1998-01-23 1999-01-22 Method for treating inflammatory diseases using heat shock proteins

Publications (2)

Publication Number Publication Date
NO20003775D0 NO20003775D0 (no) 2000-07-21
NO20003775L true NO20003775L (no) 2000-09-22

Family

ID=21754459

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003775A NO20003775L (no) 1998-01-23 2000-07-21 FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner

Country Status (16)

Country Link
US (2) US20020006410A1 (enExample)
EP (1) EP1049483A1 (enExample)
JP (1) JP2002509074A (enExample)
KR (1) KR20010040389A (enExample)
CN (1) CN1324243A (enExample)
AU (1) AU2337499A (enExample)
BR (1) BR9907228A (enExample)
CA (1) CA2318263A1 (enExample)
CZ (1) CZ20002669A3 (enExample)
HU (1) HUP0100241A2 (enExample)
IL (1) IL137404A0 (enExample)
NO (1) NO20003775L (enExample)
PL (1) PL342166A1 (enExample)
TR (1) TR200002973T2 (enExample)
WO (1) WO1999037319A1 (enExample)
ZA (1) ZA99499B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7992572B2 (en) 1998-06-10 2011-08-09 Asthmatx, Inc. Methods of evaluating individuals having reversible obstructive pulmonary disease
WO2000048622A2 (en) * 1999-02-22 2000-08-24 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
WO2001022816A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AUPR381601A0 (en) * 2001-03-19 2001-04-12 Monash University Method of treating respiratory conditions
CA2460396A1 (en) * 2001-10-01 2003-04-10 Duke University Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
KR100615389B1 (ko) * 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
US20100111927A1 (en) * 2002-08-23 2010-05-06 Sunyoung Kim Compositions Comprising Actinidia and Methods of Use Thereof
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
EP1951282A4 (en) * 2005-10-20 2009-09-02 Cbio Ltd TREATMENT OF HYPERSENSITIVITY
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
EP2391229B1 (en) 2009-01-29 2015-07-15 Alfa Biogene International B.V. Functional food product comprising heat shock protein or a hydrolysate thereof from alfalfa
EP2397074B1 (en) 2010-06-19 2012-10-24 M Stenqvist AB A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus
DK2646044T3 (da) 2010-11-30 2019-11-25 Orphazyme As Metoder til at øge den intracellulære aktivitet af Hsp70
WO2012097255A2 (en) * 2011-01-14 2012-07-19 Scott & White Healthcare Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012174549A2 (en) * 2011-06-16 2012-12-20 Children's Hospital Medical Center Blockade of eosinophil production by toll-like receptors
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
KR20250069686A (ko) 2014-09-15 2025-05-19 제브라 덴마크 에이/에스 아리모클로몰 제제
EP3402572B1 (en) 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
CN106220718B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP60及其应用
CN106243203B (zh) * 2016-08-04 2019-12-10 上海市农业科学院 一种草菇热激蛋白VvHSP70及其应用
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3781588B1 (en) 2018-04-20 2024-10-30 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
BR122023023216A2 (pt) 2018-06-27 2024-02-20 Proteostasis Therapeutics, Inc. Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN114046596B (zh) * 2021-11-17 2022-09-23 重庆大学 基于trp生化指标检测的室内空气质量控制系统及方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
DE69126668T2 (de) * 1990-11-08 1997-10-23 University College London, London Mycobacterium als adjuvans für antigene
GB9211736D0 (en) * 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
EP0941315B1 (en) * 1996-11-26 2006-03-01 Stressgen Biotechnologies Corporation Fusion proteins containing stress proteins for inducing immune responses

Also Published As

Publication number Publication date
CN1324243A (zh) 2001-11-28
EP1049483A1 (en) 2000-11-08
HUP0100241A2 (hu) 2001-06-28
PL342166A1 (en) 2001-05-21
CA2318263A1 (en) 1999-07-29
CZ20002669A3 (cs) 2001-11-14
US20070179087A1 (en) 2007-08-02
IL137404A0 (en) 2001-07-24
JP2002509074A (ja) 2002-03-26
ZA99499B (en) 1999-07-22
AU2337499A (en) 1999-08-09
BR9907228A (pt) 2000-10-24
TR200002973T2 (tr) 2001-02-21
WO1999037319A1 (en) 1999-07-29
US20020006410A1 (en) 2002-01-17
KR20010040389A (ko) 2001-05-15
NO20003775D0 (no) 2000-07-21

Similar Documents

Publication Publication Date Title
NO20003775L (no) FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner
NO991784D0 (no) Purin-L-nukleosider, analoger og anvendelser derav
NL194940B (nl) Virusstam en vaccin ter voorkoming van varkensreproductie- en -respiratiesyndroom.
EE04239B1 (et) Hüdroksüülamiini derivaadid, mis on kasutatavad molekulaarse seostusvalgu moodustumise suurendamiseks, ja nende valmistamine
NO20016007L (no) Rekombinant anti-CD40-antistoff og anvendelser derav
DE69332518D1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
EA199700413A1 (ru) Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
NO832630L (no) Trifenylimidazolyloxyalkansyrer og deres derivater, deres fremstilling og deres anvendelse i preparater
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
FI971732L (fi) Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi
NO931372L (no) Behandling av autoimmunsykdommer ved oral administrering av autoantigener
FI953608A0 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
IT1229484B (it) Virus ricombinante delle malattie esantematiche dei vertebrati.
DK1733730T3 (da) Immunmodulerende oligosaccharider
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
BR9506819A (pt) Derivados de ácido micofenólico substituídos na posiçao 5
WO1996013512A3 (en) L-ribofuranosyl nucleosides
DK1009413T3 (da) Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2192839T3 (es) Timosina beta 4 oxidada.
NO881515L (no) Pulmonar surfaktant.
BR9913446A (pt) Produtos de aglicona e métodos de uso
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
EP0593290A3 (en) Core antigen protein of the hepatitis C virus, as well as diagnostic procedure and set of reagents.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application